Nino Khetsuriani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Interests
Nino Khetsuriani has a total of 140 co-authors. Here are the top co-authors by number of shared publications:
Rebecca Martin
Centers for Disease Control and Prevention, Atlanta, Georgia World Health Organization Regional Office for Europe, Copenhagen, Denmark
4 shared publicationsEugene Gavrilin
World Health Organization Regional Office for Europe, Copenhagen, Denmark
3 shared publications- Kathleen Wannemuehler
Global Immunization Division, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333, United States
3 shared publications Liudmila Mosina
World Health Organization Regional Office for Europe, Copenhagen, Denmark
3 shared publicationsNazibrola Chitadze
National Center for Disease Control and Public Health of Georgia (NCDC), Tbilisi, Georgia
3 shared publicationsPavel Ursu
World Health Organization (WHO) Country Office, Dushanbe, Tajikistan
3 shared publications
Latest Publications
- Open Access
- 1 May 2026
- Published by Elsevier in IJID Regions
- Vol. 19
Prevalence and epidemiology of hepatitis B and hepatitis D in Uzbekistan—results from a population-based serosurvey, 2022
- 1 May 2026
- Published by Elsevier in IJID Regions
- Vol. 19
Open AccessPrevalence and epidemiology of hepatitis B and hepatitis D in Uzbekistan—results from a population-based serosurvey, 2022
- Open Access
- 27 July 2023
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 28 (30) , 2200837-23
Toward reaching hepatitis B goals: hepatitis B epidemiology and the impact of two decades of vaccination, Georgia, 2021
Background: Georgia has adopted the World Health Organization European Region’s and global goals to eliminate viral hepatitis. A nationwide serosurvey among adults in 2015 showed 2.9% prevalence for hepatitis B virus (HBV) surface antigen (HBsAg) and 25.9% for antibodies against HBV core antigen (anti-HBc). HBV infection prevalence among children had previously not been assessed. Aim: We aimed to assess HBV infection prevalence among children and update estimates for adults in Georgia. Methods: This nationwide cross-sectional serosurvey conducted in 2021 among persons aged ≥ 5 years used multi-stage stratified cluster design. Participants aged 5–20 years were eligible for hepatitis B vaccination as infants. Blood samples were tested for anti-HBc and, if positive, for HBsAg. Weighted proportions and 95% confidence intervals (CI) were calculated for both markers. Results: Among 5–17 year-olds (n = 1,473), 0.03% (95% CI: 0–0.19) were HBsAg-positive and 0.7% (95% CI: 0.3–1.6) were anti-HBc-positive. Among adults (n = 7,237), 2.7% (95% CI: 2.3–3.4) were HBsAg-positive and 21.7% (95% CI: 20.4–23.2) anti-HBc-positive; HBsAg prevalence was lowest (0.2%; 95% CI: 0.0–1.5) among 18–23-year-olds and highest (8.6%; 95% CI: 6.1–12.1) among 35–39-year-olds. Conclusions: Hepatitis B vaccination in Georgia had remarkable impact. In 2021, HBsAg prevalence among children was well below the 0.5% hepatitis B control target of the European Region and met the ≤ 0.1% HBsAg seroprevalence target for elimination of mother-to-child transmission of HBV. Chronic HBV infection remains a problem among adults born before vaccine introduction. Screening, treatment and preventive interventions among adults, and sustained high immunisation coverage among children, can help eliminate hepatitis B in Georgia by 2030.
- 27 July 2023
- Published by European Centre for Disease Control and Prevention (ECDC) in Eurosurveillance
- Vol. 28 (30) , 2200837-23
Open AccessToward reaching hepatitis B goals: hepatitis B epidemiology and the impact of two decades of vaccination, Georgia, 2021
Background: Georgia has adopted the World Health Organization European Region’s and global goals to eliminate viral hepatitis. A nationwide serosurvey among adults in 2015 showed 2.9% prevalence for hepatitis B virus (HBV) surface antigen (HBsAg) and 25.9% for antibodies against HBV core antigen (anti-HBc). HBV infection prevalence among children had previously not been assessed. Aim: We aimed to assess HBV infection prevalence among children and update estimates for adults in Georgia. Methods: This nationwide cross-sectional serosurvey conducted in 2021 among persons aged ≥ 5 years used multi-stage stratified cluster design. Participants aged 5–20 years were eligible for hepatitis B vaccination as infants. Blood samples were tested for anti-HBc and, if positive, for HBsAg. Weighted proportions and 95% confidence intervals (CI) were calculated for both markers. Results: Among 5–17 year-olds (n = 1,473), 0.03% (95% CI: 0–0.19) were HBsAg-positive and 0.7% (95% CI: 0.3–1.6) were anti-HBc-positive. Among adults (n = 7,237), 2.7% (95% CI: 2.3–3.4) were HBsAg-positive and 21.7% (95% CI: 20.4–23.2) anti-HBc-positive; HBsAg prevalence was lowest (0.2%; 95% CI: 0.0–1.5) among 18–23-year-olds and highest (8.6%; 95% CI: 6.1–12.1) among 35–39-year-olds. Conclusions: Hepatitis B vaccination in Georgia had remarkable impact. In 2021, HBsAg prevalence among children was well below the 0.5% hepatitis B control target of the European Region and met the ≤ 0.1% HBsAg seroprevalence target for elimination of mother-to-child transmission of HBV. Chronic HBV infection remains a problem among adults born before vaccine introduction. Screening, treatment and preventive interventions among adults, and sustained high immunisation coverage among children, can help eliminate hepatitis B in Georgia by 2030.
- 30 July 2021
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 70 (30) , 1029-1035
Progress Toward Hepatitis B Control — World Health Organization European Region, 2016–2019
This report describes progress toward hepatitis B control in the World Health Organization European Region.
- 30 July 2021
- Published by Centers for Disease Control MMWR Office in MMWR. Morbidity and Mortality Weekly Report
- Vol. 70 (30) , 1029-1035
Progress Toward Hepatitis B Control — World Health Organization European Region, 2016–2019
This report describes progress toward hepatitis B control in the World Health Organization European Region.
- 1 November 2020
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 26 (11) , 2565-2577
Challenges to Achieving Measles Elimination, Georgia, 2013–2018
Controlling measles outbreaks in the country of Georgia and throughout Europe is crucial for achieving the measles elimination goal for the World Health Organization’s European Region. However, large-scale measles outbreaks occurred in Georgia during 2013–2015 and 2017–2018. The epidemiology of these outbreaks indicates widespread circulation and genetic diversity of measles viruses and reveals persistent gaps in population immunity across a wide age range that have not been sufficiently addressed thus far. Historic problems and recent challenges with the immunization program contributed to outbreaks. Addressing population susceptibility across all age groups is needed urgently. However, conducting large-scale mass immunization campaigns under the current health system is not feasible, so more selective response strategies are being implemented. Lessons from the measles outbreaks in Georgia could be useful for other countries that have immunization programs facing challenges related to health-system transitions and the presence of age cohorts with historically low immunization coverage.
- 1 November 2020
- Published by Centers for Disease Control and Prevention (CDC) in Emerging Infectious Diseases
- Vol. 26 (11) , 2565-2577
Challenges to Achieving Measles Elimination, Georgia, 2013–2018
Controlling measles outbreaks in the country of Georgia and throughout Europe is crucial for achieving the measles elimination goal for the World Health Organization’s European Region. However, large-scale measles outbreaks occurred in Georgia during 2013–2015 and 2017–2018. The epidemiology of these outbreaks indicates widespread circulation and genetic diversity of measles viruses and reveals persistent gaps in population immunity across a wide age range that have not been sufficiently addressed thus far. Historic problems and recent challenges with the immunization program contributed to outbreaks. Addressing population susceptibility across all age groups is needed urgently. However, conducting large-scale mass immunization campaigns under the current health system is not feasible, so more selective response strategies are being implemented. Lessons from the measles outbreaks in Georgia could be useful for other countries that have immunization programs facing challenges related to health-system transitions and the presence of age cohorts with historically low immunization coverage.
- Open Access
- 11 December 2019
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 147, e319
Measles and rubella seroprevalence among adults in Georgia in 2015: helping guide the elimination efforts
A large-scale measles outbreak (11 495 reported cases, 60% aged ≥15 years) occurred in Georgia during 2013–2015. A nationwide, multistage, stratified cluster serosurvey for hepatitis B and C among persons aged ≥18 years conducted in Georgia in late 2015 provided an opportunity to assess measles and rubella (MR) susceptibility after the outbreak. Residual specimens from 3125 participants aged 18–50 years were tested for Immunoglobulin G antibodies against MR using ELISA. Nationwide, 6.3% (95% CI 4.9%–7.6%) of the surveyed population were seronegative for measles and 8.6% (95% CI 7.1%–10.1%) were seronegative for rubella. Measles susceptibility was highest among 18–24 year-olds (10.1%) and declined with age to 1.2% among 45–50 year-olds (P< 0.01). Susceptibility to rubella was highest among 25–29 year-olds (15.3%), followed by 18–24 year-olds (11.6%) and 30–34 year-olds (10.2%), and declined to P< 0.001). The susceptibility profiles in the present serosurvey were consistent with the epidemiology of recent MR cases and the history of the immunization programme. Measles susceptibility levels >10% among 18–24 year-olds in Georgia revealed continued risk for outbreaks among young adults. High susceptibility to rubella among 18–34 year-olds indicates a continuing risk for congenital rubella cases.
- 11 December 2019
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 147, e319
Open AccessMeasles and rubella seroprevalence among adults in Georgia in 2015: helping guide the elimination efforts
A large-scale measles outbreak (11 495 reported cases, 60% aged ≥15 years) occurred in Georgia during 2013–2015. A nationwide, multistage, stratified cluster serosurvey for hepatitis B and C among persons aged ≥18 years conducted in Georgia in late 2015 provided an opportunity to assess measles and rubella (MR) susceptibility after the outbreak. Residual specimens from 3125 participants aged 18–50 years were tested for Immunoglobulin G antibodies against MR using ELISA. Nationwide, 6.3% (95% CI 4.9%–7.6%) of the surveyed population were seronegative for measles and 8.6% (95% CI 7.1%–10.1%) were seronegative for rubella. Measles susceptibility was highest among 18–24 year-olds (10.1%) and declined with age to 1.2% among 45–50 year-olds (P< 0.01). Susceptibility to rubella was highest among 25–29 year-olds (15.3%), followed by 18–24 year-olds (11.6%) and 30–34 year-olds (10.2%), and declined to P< 0.001). The susceptibility profiles in the present serosurvey were consistent with the epidemiology of recent MR cases and the history of the immunization programme. Measles susceptibility levels >10% among 18–24 year-olds in Georgia revealed continued risk for outbreaks among young adults. High susceptibility to rubella among 18–34 year-olds indicates a continuing risk for congenital rubella cases.
- 11 November 2019
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 26 (6) , 737-742
High risk of subacute sclerosing panencephalitis following measles outbreaks in Georgia
- 11 November 2019
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 26 (6) , 737-742
High risk of subacute sclerosing panencephalitis following measles outbreaks in Georgia